Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation.
about
Light chain (AL) amyloidosis: update on diagnosis and managementCD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapyImmunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatmentUpdate on treatment of light chain amyloidosisAmyloid diseases of the heart: current and future therapiesChronic diarrhea as the initial clinical manifestation of light-chain amyloidosis with cardiac involvement despite negative duodenal and rectal biopsies.Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation.An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis.Bortezomib, melphalan, and prednisolone combination chemotherapy for newly diagnosed light chain (AL) amyloidosis.Phase 1 study of bortezomib in combination with melphalan and dexamethasone in Japanese patients with relapsed AL amyloidosis.Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myelomaAmyloidosis and POEMS syndrome.Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score.A dilemma solved.Unfolded protein response activation reduces secretion and extracellular aggregation of amyloidogenic immunoglobulin light chainKidney dysfunction during lenalidomide treatment for AL amyloidosis.Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trialAmyloidosis: pathogenesis and new therapeutic options.Macroglossia due to Systemic Amyloidosis: Is There a Role for Radiotherapy?Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantationLenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial.Single Nodular Pulmonary Amyloidosis: Case Report.Al amyloidosisIncomplete ileus and hemafecia as the presenting features of multi-organ involved primary systemic AL amyloidosis: a rare case report.Autologous stem cell transplantation and IgM amyloidosis.Clinical profile and treatment outcome of older (>75 years) patients with systemic AL amyloidosis.Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trialA phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis.Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.Perspectives in treatment of AL amyloidosis.Amyloidosis: 2008 BMT Tandem Meetings (February 13-17, San Diego).Cardiac amyloidosis masquerading as biventricular hypertrophy in a patient with multiple myelomaChanges in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosisLenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement.Hepatic response after high-dose melphalan and stem cell transplantation in patients with AL amyloidosis associated liver disease.Histological regression of amyloid in AL amyloidosis is exclusively seen after normalization of serum free light chainOral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach.Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management.Cardiac amyloidosis: the heart of the matter.
P2860
Q21198863-201ADF13-49AF-4B46-83D4-2AB5D7CE77EBQ24649764-3578296B-3651-4503-98DE-45095CFCFE05Q26827340-60C375E2-4F98-4D59-A19D-A25F8EF71B60Q26829735-CB3E751A-C6AD-4429-AF94-B0ECFFD63B9AQ27023836-D79AC03C-BFFB-4159-9AE2-CCC8943F8116Q33163149-C41F3F16-03D9-4B86-8AA6-F8AC040C9DDCQ33292965-D8A9986E-6A88-40DD-95E6-D23D4CD0B72BQ33304297-FC66D436-AB97-486F-9A30-72616B40B5E1Q33417805-D5BEDE14-1C56-4E35-9658-831941C7C86EQ33427726-979ED548-AC8E-4829-AA92-E4F8B290F80EQ33744195-B91DCB74-9CB3-4BA6-AA5D-5D54F9EFFD06Q33867198-A938FFCF-BAC0-46F7-B6CD-D2C07416F9D0Q34448455-5EB66AD2-2D9E-4011-B268-EA7C73D988F6Q34450910-15C87268-0C02-46EE-ABB2-2D5D2A2C9C55Q34522518-23DB8E9E-AD38-40C9-BC55-3CAFA61BBDA9Q34583702-04293C61-825A-4005-80B5-FA67207A2953Q35025410-4E813EDD-81C6-41C8-9337-BBC39425B43DQ35081363-F8BF29C7-0D44-41AC-88E2-CC0D00C8783BQ35111771-7E3B7ACC-4908-47D6-B6DB-BB0892F670B2Q35225655-D4881244-B9F5-43BA-BAA7-B40A95A65DFDQ35849610-D6DC484D-326F-43BA-847E-96671E6D87D4Q36163205-1CFBD1A3-E09B-4FBB-9685-E871F48F104BQ36205516-448C17AF-F89C-44C6-864C-115A6CECEA66Q36392233-8FD3F450-0C10-4866-8942-37B412F1205FQ36393248-BADC6957-8D3D-4A5B-AE8D-3D9314D73C2FQ36535491-41E337FE-0F41-4BF6-B712-B5572E4E2D62Q36779759-D5D4299C-BA5D-4888-9A7E-354B015CA376Q36805878-9F3D4A7E-4292-4AC1-8C3B-181ACB592103Q36862339-1FA6B26D-4776-4535-AC63-DD1ED1147397Q36910372-4A10706D-EF7C-4979-9D6A-1F60A1BA83AFQ37045885-6A70BC5A-2CBF-44D4-801C-79664D8DB917Q37045900-0BAE6F15-6088-4364-9DA4-B7478BBF95A9Q37077026-09F0E9AE-E142-459B-A972-BF92996E43D2Q37172003-5F79DEAE-2CB2-4603-BA51-01F804F9E11CQ37212712-467B9A3D-2F13-46D2-BD32-DA330393A627Q37246780-E87D6621-675D-4188-9F8C-9CAA49AFA76CQ37284404-7EBEBF15-9B2D-4150-BBF0-5718B3605051Q37676296-4DCB4FD4-F18C-4F57-ACA2-F5306F0EA0A3Q37832199-5A49C861-2C69-4ADC-9521-BA5F798FFCB4Q37899075-8A6BC079-557E-4577-AEF7-D9922282E496
P2860
Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation.
description
2003 nî lūn-bûn
@nan
2003 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Association of melphalan and h ...... for stem cell transplantation.
@ast
Association of melphalan and h ...... for stem cell transplantation.
@en
Association of melphalan and h ...... tolerated in patients with AL
@nl
type
label
Association of melphalan and h ...... for stem cell transplantation.
@ast
Association of melphalan and h ...... for stem cell transplantation.
@en
Association of melphalan and h ...... tolerated in patients with AL
@nl
prefLabel
Association of melphalan and h ...... for stem cell transplantation.
@ast
Association of melphalan and h ...... for stem cell transplantation.
@en
Association of melphalan and h ...... tolerated in patients with AL
@nl
P2093
P50
P1433
P1476
Association of melphalan and h ...... for stem cell transplantation
@en
P2093
Alessandra Semino
Fausto Adami
Giobatta Cavallero
Giovambattista Virga
Roberto Rustichelli
Vittorio Perfetti
P304
P356
10.1182/BLOOD-2003-08-2788
P407
P577
2003-12-18T00:00:00Z